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role in ROS/NO signaling during microglial
activation through the lipoxygenase
pathway
Dennis Y. Chuang1,2,3, Agnes Simonyi2,3,4, Paul T. Kotzbauer5, Zezong Gu1,2,3,6 and Grace Y. Sun1,2,3,4*

Abstract
Background: Oxidative stress and inflammation are important factors contributing to the pathophysiology of
numerous neurological disorders, including Alzheimer’s disease, Parkinson’s disease, acute stroke, and infections of the
brain. There is well-established evidence that proinflammatory cytokines and glutamate, as well as reactive oxygen
species (ROS) and nitric oxide (NO), are produced upon microglia activation, and these are important factors
contributing to inflammatory responses and cytotoxic damage to surrounding neurons and neighboring cells.
Microglial cells express relatively high levels of cytosolic phospholipase A2 (cPLA2), an enzyme known to regulate
membrane phospholipid homeostasis and release of arachidonic acid (AA) for synthesis of eicosanoids. The goal for
this study is to elucidate the role of cPLA2IV in mediating the oxidative and inflammatory responses in microglial cells.
Methods: Experiments involved primary microglia cells isolated from transgenic mice deficient in cPLA2α or iPLA2β, as
well as murine immortalized BV-2 microglial cells. Inhibitors of cPLA2/iPLA2/cyclooxygenase (COX)/lipoxygenase (LOX)
were used in BV-2 microglial cell line. siRNA transfection was employed to knockdown cPLA2 expression in BV-2 cells.
Griess reaction protocol was used to determine NO concentration, and CM-H2DCF-DA was used to detect ROS
production in primary microglia and BV-2 cells. WST-1 assay was used to assess cell viability. Western blotting was used
to assess protein expression levels. Immunocytochemical staining for phalloidin against F-actin was used to
demonstrate cell morphology.
Results: In both primary and BV-2 microglial cells, stimulation with lipopolysaccharide (LPS) or interferon gamma (IFNγ)
resulted in a time-dependent increase in phosphorylation of cPLA2 together with ERK1/2. In BV-2 cells, LPS- and IFNγinduced ROS and NO production was inhibited by arachidonyl trifluoromethyl ketone (AACOCF3) and pyrrophenone
as well as RNA interference, but not BEL, suggesting a link between cPLA2, and not iPLA2, on LPS/IFNγ-induced
nitrosative and oxidative stress in microglial cells. Primary microglial cells isolated from cPLA2α-deficient mice
generated significantly less NO and ROS as compared with the wild-type mice. Microglia isolated from iPLA2β-deficient
mice did not show a decrease in LPS-induced NO and ROS production. LPS/IFNγ induced morphological changes in
primary microglia, and these changes were mitigated by AACOCF3. Interestingly, despite that LPS and IFNγ induced an
increase in phospho-cPLA2 and prostaglandin E2 (PGE2) release, LPS- and IFNγ-induced NO and ROS production were
not altered by the COX-1/2 inhibitor but were suppressed by the LOX-12 and LOX-15 inhibitors instead.
(Continued on next page)
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Conclusions: In summary, the results in this study demonstrated the role of cPLA2 in microglial activation with
metabolic links to oxidative and inflammatory responses, and this was in part regulated by the AA metabolic pathways,
namely the LOXs. Further studies with targeted inhibition of cPLA2/LOX in microglia during neuroinflammatory
conditions can be valuable to investigate the therapeutic potential in ameliorating neurological disease pathology.
Keywords: Microglia, cPLA2, Arachidonic acid, Lipoxygenase, ROS, NO

Background
Neuroinflammation plays a major role in the progression
of neurodegenerative diseases including Alzheimer’s disease, Parkinson’s diseases, cerebral vascular stroke, and infectious HIV encephalopathy. Microglial cells, the resident
innate immune cells in the central nervous system (CNS),
are known to exert multiple physiologic functions in the
brain, including anchoring CNS innate immune response
through phagocytosis of foreign pathogens, removing
cellular breakdown products, stimulating tissue repair
process, and maintaining tissue homeostasis [1]. Activation of microglial cells can also exert significant impact on
the propagation of inflammatory responses [2, 3]. For instance, activated microglia was shown in vivo to contribute to expansion of infarct after focal cerebral ischemia
[4], and inhibition of microglial activation was proven a viable strategy to prevent inflammatory neuronal death in
vitro [5]. Recent studies had place much focus on the differential functions of polarized M1/M2 microglial cells
after activation. While much research is currently underway to distinguish the biochemical and functional properties of each phenotype, most tend to agree that M1
microglia are more cytotoxic and persist during the disease effector stage, whereas M2 microglia are more neuroprotective and predominate during the repair stage [6–8].
The discovery of functional differences and delineation of
time course of microglia polarization has generated interest in ways to limit M1 activation and stimulate M2 transformation in order to ameliorate outcomes of neurological
diseases, including experimental stroke and traumatic
brain injury [9–13].
Biochemically, M1 microglial activation is associated
with the release of ROS, NO, glutamate, cytokines (such
as TNFα), phospholipases, matrix metalloproteases, and
other proinflammatory factors contributing to the progressive neuronal damage observed in many neurodegenerative disorders [14–16]. Therefore, suppressing or
limiting microglial activation can have beneficial effects
for preventing neuroinflammation and neurodegeneration. Microglia in vitro can be activated with a variety of
agents, such as proinflammatory cytokines (TNFα, IL1β, IFNγ), lipopolysaccharides (LPS), and oligomeric
beta amyloid (Aβ) [17]. Studies including those from our
laboratory have demonstrated that microglia activation
by proinflammatory cytokines and LPS causes induction

of iNOS and activation of NADPH oxidase, leading to
increased oxidative/nitrosative stress [18].
Phospholipase A2s (PLA2s) are groups of enzymes that
hydrolyze the fatty acids from the sn-2 position of
membrane phospholipids. Among the PLA2s identified,
cPLA2 and iPLA2 are the constitutively active PLA2s
that serve as important mediators for the release of polyunsaturated fatty acids, including arachidonic acid (AA)
and docosahexaenoic acid from membrane phospholipids [19, 20]. Multiple studies have demonstrated group
IV PLA2α (cPLA2α) to be the major PLA2 responsible
for the release of AA and to play an essential role in inflammation. Transgenic mice lacking cPLA2α have been
shown to display significantly reduced deleterious phenotypes in inflammatory diseases, such as ischemic brain
injury, anaphylaxis, arthritis, alcoholism, and acute lung
injury [21–27]. More recent in vivo studies demonstrated ability for pharmacological inhibitors of cPLA2 to
ameliorate ischemic stroke, experimental autoimmune
encephalitis, and spinal cord injury [28–30]. Although
cPLA2 activation in the brain is associated with oxidative
stress, neuronal excitation, and neuroinflammation [31],
little is known about mechanism(s) for its activation in
microglial cells [32]. Previous studies demonstrated
protective effects of cPLA2 inhibition against microgliainduced white matter damage in vivo and oligodendrocyte cell death in vitro, suggesting the role of this
enzyme as a potential target to suppress microgliainduced secondary damage in the central nervous system
[30]. However, the mode of action of cPLA2 and its link
to the inflammatory responses in microglial cells have
not been elucidated in detail. In this study, we isolated
primary microglial cells from cPLA2 and iPLA2 KO mice
to demonstrate the role of cPLA2 (and not iPLA2) in
mediating oxidative and inflammatory responses from
LPS and IFNγ stimulation. In addition, we further suggested a mechanism that links cPLA2-mediated eicosanoid
production with downstream ROS and NO generation in
BV-2 microglial cells.

Methods
Materials

Dulbecco’s modified Eagle’s medium (DMEM), penicillin/
streptomycin, and 0.25 % (w/v) trypsin/EDTA were obtained from GIBCO (Gaithersburg, MD). Endotoxin-free
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fetal bovine serum was from Atlanta Biologicals
(Lawrenceville, GA). Lipopolysaccharide (LPS) (rough
strains) from Escherichia coli F583 (Rd mutant) was purchased from Sigma-Aldrich (St. Louis, MO). Interferon-γ
(IFNγ) was purchased from R&D Systems (Minneapolis,
MN). Pharmacological inhibitors used include the following: U0126, SB202190, and SP600125 were from Cell Signaling (Beverly, MA). Arachidonyl trifluoromethyl ketone
(AACOCF3), pyrrophenone, racemic bromoenol lactone
(BEL), nordihydroguaiaretic acid (NDGA), ibuprofen,
zileuton, and PD146176 were from Cayman Chemical
(Ann Arbor, MI). NCTT-956 was from Sigma-Aldrich
(St. Louis, MO). RNA interference Lipofectamine
RNAiMAX Transfection Reagent was from Life Technology (Carlsbad, CA). siRNA against cPLA2 Mm_Pla2g4a_8
FlexiTube siRNA (NM_008869) and AllStars Negative
Control siRNA were purchased from Qiagen (Hilden,
Germany). Antibodies used for Western blots include the
following: goat anti-rabbit IgG-horseradish peroxidase,
goat anti-mouse IgG-horseradish peroxidase, anti-cPLA2
rabbit polyclonal, anti-iNOS rabbit polyclonal antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA); monoclonal
anti-β-actin peroxidase (Sigma-Aldrich, St. Louis, MO);
rabbit polyclonal anti-p-cPLA2, rabbit polyclonal antiERK1/2, and mouse monoclonal anti-phospho-ERK1/2
antibodies (Cell Signaling, Beverly, MA). An affinitypurified antibody directed against an iPLA2β peptide corresponding to residues 277–295 was a gift of Drs. Chris
Jenkins and Richard Gross (Washington University School
of Medicine, St. Louis, MO) [33]. For immunocytochemical staining, rabbit anti-ionized calcium-binding adapter
molecule 1 (Iba-1) antibodies (019–19741) was purchased
from Wako BioProducts (Richmond, VA), Alexa Fluor
488® phalloidin from Life Technologies (Carlsbad, CA),
and 4′,6-diamidino-2-phenylindole (DAPI) from Roche
Molecular Chemicals (Basel, Switzerland). For ROS detection, CM-H2DCF-DA (DCF) was purchased from Invitrogen, Inc. (Eugene, OR). WST-1 assay was purchased from
Clontech (Mountain View, CA). Prostaglandin E2 (PGE2)
EIA Kit was purchased from Cayman Chemicals (Ann
Arbor, MI).
cPLA2 transgenic animal breeding and genotyping

All animal care and experimental protocols were carried
out in accordance with NIH guidelines and with permission from the University of Missouri Animal Care and
Use Committee (protocol #6728). Pairs of C57Bl/6 male
and female heterozygous cPLA2+/− mice were kindly
provided by Dr Joseph V. Bonventre (Harvard Medical
School, Boston, MA) and colony was expanded at the
University of Missouri for more than five generations
prior to start of the experiments. Wild-type cPLA2+/+
and homozygous knockout cPLA2−/− mice used in the
experiments were generated by crossing male and female
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heterozygous cPLA2+/− mice, and genotyping of litters
was done between postnatal day 3~6 by polymerase
chain reaction (PCR) as previously described [21].
iPLA2 transgenic animal breeding and genotyping

iPLA2β-KO mice were housed and cared for in animal facilities administered through the Washington University
Division of Comparative Medicine, and animal procedures
were performed according to a protocol approved by
the Washington University Animal Studies Committee.
iPLA2β-KO mice were previously generated by insertion
of the neomycin resistance gene into exon 9 of the mouse
iPLA2β (Pla2g6) gene by homologous recombination
[34, 35]. KO and WT mice were generated by mating heterozygous mice, and their genotype was determined by a
PCR assay. The primers used for PCR genotyping
were WT F1 (TTACCTCCGCTTCTCGTCCCTCATG
GAGCT), Neo F1 (GGGAACTTCCTGACTAGGGGAG
GAGTAGAA), and WT R1 (TCTGTTTCTCTAGA
GACCCATGGGGCCTTG), which when combined in a
single PCR reaction generate a 158-bp band for the WT
allele and a 254-bp band for the KO allele.
Primary microglia isolation

Preparations of primary microglial cells with postnatal day
7–10 C57Bl/6 pups were accomplished with the Miltenyi
Biotec MACS cell separation system (Bergisch Gladbach,
Germany). Briefly, brains from the genotyped pups were
dissected and meninges removed. Tissues were dissociated
using the Neural Tissue Dissociation Kit (P) (Miltenyi
Biotec) with the gentleMACS dissociator. Prior to isolation, cell concentration in the suspension was counted
and roughly 105 cells were collected for flow cytometry
analysis by the Cellular Immunology Core in the University of Missouri. Microglia were isolated from the singlecell suspension using the magnetic activated cell sorting
(MACS) technology with anti-cluster of differentiation
molecule 11b (CD11b) (Microglia) MicroBeads (Miltenyi
Biotec) in combination with an OctoMACS Separator
with slight modifications to the manufacturer’s instructions. The number of cells post-isolation was counted, and
roughly 105 cells were collected for post-isolation flow
cytometry analysis, and the remaining cells were plated at
a density of 5 × 105/cm2. Plated cells were cultured in
DMEM supplemented with 10 % FBS containing
100 units/mL penicillin and 100 μg/mL streptomycin and
maintained in 5 % CO2 incubator at 37 °C. Culture
medium was replaced every 3–5 days. Primary cell cultures
were used between days-in-vitro (DIV)5–7.
Immortalized microglial BV-2 cell culture

The murine BV-2 cell line was generated by infecting
primary microglia cell cultures with a v-raf/v-myc
oncogene-carrying retrovirus (J2) [36]. These cells were
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obtained as a gift from Dr. R. Donato [37] and prepared
as previously described [18, 38]. Briefly, cells were cultured in DMEM (high glucose) supplemented with 10 %
FBS containing 100 units/mL penicillin and 100 μg/mL
streptomycin and maintained in 5 % CO2 incubator at
37 °C. For subculture, cells were removed from the culture flask by gentle scraping, re-suspended in the culture
medium, and sub-cultured in 6/96-well plates for experiments. Cell condition and morphology were assessed by
using a phase contrast Nikon DIAPHOT 300 microscope attached with a CCD cool camera, and MagnaFire2.1C software was used for image capture and
processing. Representative bright field pictures were obtained using a 20× objective lens.
Flow cytometry for microglial cell purity analysis

During primary microglia isolation, after tissue dissociation and cell number were determined, roughly 105
cells were collected, resuspended in 100 μL buffer, and
incubated with 10 μL CD11b-fluorescein isothiocyanate
(FITC) antibodies (Miltenyi) for 10 min in 4 °C. Cells
were then washed and resuspended in 100 μL fresh buffer for flow cytometry analysis. Similarly, after microglia
isolating by CD11b cell sorting, 105 cells were collected
and labeled with cd11b-FITC for flow cytometry analysis. Flow cytometry analysis was performed using the
BD FACScan under the FITC protocol by the Cellular
Immunology Core in the University of Missouri.
cPLA2 RNA interference knockdown in BV-2 cells

BV-2 cells were seeded in 96- and 24-well plates with
antibiotic-free DMEM containing 5 % FBS for 24 h.
When cell density reached roughly 70–80 %, they were
transfected with either AllStars negative control siRNA
(Qiagen) or cPLA2 siRNA (NM_008869, Qiagen) (final
concentration of 40 nM) using the RNAiMAX transfection reagent (Invitrogen) in mixture of Opti-MEM and
DMEM mediums for 48 h prior to being used for experiments, according to the manufacturer’s instructions.
cPLA2 knockdown was evaluated by Western blot for
protein expression of total cPLA2 normalized against
β-actin.
Cell viability assay protocol

The WST-1 protocol was used for assessment of cell viability. Briefly, after reaching 80–90 % confluence, cells in
96-well plates were serum starved for 4 h, followed by
incubation with inhibitors for 16 h. After treatment, cell
viability was determined by adding 10 μL of the WST-1
reagent (Roche Applied Science, Germany) into each
well. After gentle shaking, cells were incubated for 1 h at
37 °C and absorbance was read at 450 nm (with reference wavelength at 650 nm).
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NO determination

NO released from BV-2 cells was converted to nitrite in
the culture medium. NO concentration was measured
using the Griess reagent protocol as described previously
[18]. In brief, BV-2 cells in 96-well plate were serum
starved in phenol red-free DMEM for 3 h, followed by
incubation with designated inhibitors for 1 h. Cell were
then incubated with IFNγ or LPS at 37 °C for 16 h. Alternatively, primary microglia were stimulated with IFNγ
or LPS at 37 °C for 24/48 h. Aliquots of medium (50 μL)
were incubated with 50 μL of the reagent A [1 % (w/v)
sulfanilamide in 5 % phosphoric acid, Sigma-Aldrich] for
10 min at room temperature covered in dark. This was
followed by addition of 50 μL of reagent B [0.1 %, w/v,
N-1-naphthylethylenediamine dihydrochloride, SigmaAldrich] for 10 min at room temperature, protected
from light, and absorbance at 543 nm was measured
using a microplate reader (Biotek Synergy 4, Winooski,
VT). Serial dilutions of sodium nitrite (0–100 μM) were
used to generate the nitrite standard curve.
ROS determination

ROS production in microglial cells was assessed with 5(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCF-DA, or DCF in short). Primary
microglia or BV-2 microglial cells were seeded in 96-well
plate and grown until 90 % confluent. Cells were serum
starved for 3 h, followed by pretreatment with inhibitors
for 1 h, prior to stimulation with LPS or IFNγ for 11 h. Alternatively, primary microglia were stimulated with IFNγ
or LPS at 37 °C for 24/48 h. DCF (10 μM) was added to
each well and incubated for 1 h. The fluorescent intensity
of DCF was measured with a microplate reader (excitation wavelength of 490 nm and emission wavelength of
520 nm). Fluorescent intensity was normalized against
control wells for statistical analysis.
PGE2 ELISA protocol

PGE2 concentration in the cell-conditioned medium
was assessed with the PGE2 ELISA protocol (Cayman
Chemicals). Briefly, 50 μL of conditioned medium from
treated BV-2 cells in 96-well plates were incubated with
50 μL of PGE2 monoclonal antibody and 50 μL of PGE2
AChE tracer for 18 h at 4 °C with plate covered with plastic film. Standard curve was generated with serial dilution
of PGE2 EIA standard (Cayman No. 414014) in EIA buffer
prepared according to Cayman’s protocol. On day 2,
100 dtn of Ellman’s Reagent was reconstituted with 20 mL
of UltraPure water and 200 μL added into each sample/
standard well for development. The plate was placed on
an orbital shaker for 60 min prior to measuring for absorbance at 410 nm using a microplate reader. Concentration was calculated from the fourth-degree polynomial
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curve generated from the standard wells in accordance to
kit instruction.
Western blot analysis

Cell lysates were collected in RIPA buffer containing
50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 % Nonidet
P-40, and 0.1 % SDS. The extract was centrifuged at
10,000×g for 15 min at 4 °C and transferred to a clean tube
to remove cell debris. Protein concentration was measured
and normalized with the BCA protein assay kit (Pierce
Biotechnology, Rockford, IL). Depending on the target of
interest, 5–10 μg of total protein was loaded in SDSPAGE for electrophoresis. After electrophoresis, proteins
were transferred to 0.45-μm nitrocellulose membranes.
Membranes were incubated in Tris-buffered saline containing 0.1 % Tween 20 (TBS-T) and 5 % non-fat milk for
1 h at room temperature. The blots were incubated at 4 °C
overnight with antibodies cPLA2 (1:1000), phospho-cPLA2
(1:1000), ERK1/2 (1:2000), phospho-ERK1/2 (1:1000),
iNOS polyclonal (1:1000), and β-actin (1:50,000). After repeated washing with 1X TBS-T, blots were incubated with
goat anti-rabbit IgG-HRP (1:4000) or goat anti-mouse
IgG-HRP (1:2000) for 1 h at room temperature. Immunolabeling was detected by chemiluminescence ECL/
WestPico/Femto and developed in X-ray film developer. Films were scanned, and the optical density of
bands was measured with the QuantityOne software
(BioRad, Hercules, CA).
Immunocytochemistry staining

Immunocytochemistry staining was carried out as previously described by Chuang et al. [39]. Briefly, cells were
cultured in 24-well plates containing round cover slips.
After treatment, cells were fixed in 4 % paraformaldehyde for 15 min and then permeabilized with 0.1 % Triton X-100 in PBS for 30 min. Cells were incubated with
10 % normal goat serum in 0.005 % Triton X-100 in PBS
for 60 min then incubated overnight in 0.5 % normal
goat serum in 0.005 % Triton X-100 in PBS containing
primary antibodies. The next day, cells were incubated
in 0.005 % Triton X-100 in PBS containing secondary
antibodies, goat-anti-rabbit Alexa fluor 488 (Jackson
Immunoresearch), and goat-anti-mouse Alexa fluor 549
(Jackson Immunoresearch) for 60 min, followed by 1 unit
of Alexa Fluor 488 phalloidin (Life Technologies)/well
for 20 min (5 μL of 6.6 μM stock solution dissolved in
methanol diluted in 200 μL of 0.005 % Triton X-100
in PBS), and nuclear counterstaining with 1 μg/mL of
4,6-diamidine-2-phenylindole dihydrochloride (DAPI)
(Pierce) in PBS for 10 min. The coverslips were then
mounted on fluoromount (Sigma-Aldrich) and sealed
with nail polish. Fluorescence photomicrographs were
captured using a Leica DMI 6000B fully automated
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epifluorescence microscope (Leica Microsystems Inc.,
Buffalo Grove, IL).
Statistical analysis

Data were presented as means ± SEM. Results were analyzed either by one-way ANOVA followed by Dunnett’s
multiple comparison tests (V4.00; GraphPad Prism Software Inc., San Diego, CA). Statistical significance was considered for P < 0.05.

Results
Stimulation of iNOS, p-ERK1/2, and p-cPLA2 protein
expression by LPS and IFNγ in primary and immortalized
(BV-2) microglial cells

In this study, we first characterized primary microglial
cells isolated from 7–10 days postnatal c57bl/6 WT and
cPLA2 KO mouse brains using the Miltenyi Biotec
MACS protocol. Flow cytometry analysis showed 14 %
of cells from the homogenized brain tissues to express
CD11b surface antigen (microglia) prior to cell sorting/
isolation (Fig. 1a). After MACS isolation, more than
90 % of isolated cells were CD11b positive, indicating
relatively high purity from the isolation protocol (Fig. 1b).
Immunocytochemistry staining with antibodies targeted
against CD11b followed by fluorescent microscopy demonstrated staining in nearly all cells with morphology
that resembled ramified microglial cells (Fig. 1c).
Our earlier studies have demonstrated the ability for
BV-2 microglial cells to upregulate iNOS and produce
NO after LPS or IFNγ stimulation individually and proposed ERK1/2 as one of the central components in mediating this transcriptional process [39, 40]. In this
study, a time course study was carried out to test induction of iNOS, p-ERK1/2, and p-cPLA2 by LPS and IFNγ
using primary cells and compare with BV-2 microglial
cells. When primary microglial cells were stimulated
with LPS (200 ng/mL), ERK1/2 was phosphorylated
within an hour and started to decline after 2 h albeit
remaining elevated up to 24 h compared with baseline
(Fig. 2a). Following the increase in pERK1/2, LPS also
induced increase in cPLA2 phosphorylation, with maximal expression occurring at 4 h prior to a gradual decline (Fig. 2a). On the other hand, iNOS expression was
not observed until after 8 h and was highest at 24 h
(Fig. 2a). A similar expression profile was observed when
primary microglia was stimulated with IFNγ (20 ng/mL),
although the sequence of events appeared to be delayed
with ERK1/2 phosphorylation maxing at 4 h, cPLA2
phosphorylation maxing at 8 h, and iNOS expression
not observed until 16 h post-stimulation (Fig. 2b). With
IFNγ, p-cPLA2 remained upregulated at 24 h poststimulation. There were no significant changes in total
ERK1/2 or cPLA2 protein during the activation process.
When the same conditions were subjected to BV-2 cells,
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Fig. 1 (See legend on next page.)
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(See figure on previous page.)
Fig. 1 Determination of primary culture purity after isolation from brains of postnatal day 7–10 c57bl/6 mice. a Flow cytometry of cells from
pre-sorting showed 14.43 % of cells in cell suspension positive for cd11b-FITC. b Flow cytometry of cells from post-sorting showed 90.61 % of
cells in cell suspension positive for cd11b-FITC. c Immunocytochemical staining of cells in DIV5 primary culture showed expression of cd11b (red)
in almost all cells

matching trends were observed among the proteins of
interest (Fig. 2c, d), with exception that LPS stimulation
of p-ERK1/2 and p-cPLA2 appeared to be stronger than
the primary microglial cells and remained upregulated at
24 h. These results suggest the use of BV-2 cells as a justified model system to investigate biochemical profiles of
our pathway of interest during microglial activation.
cPLA2 phosphorylation is regulated by phospho-ERK1/2

Among multiple sites, Ser505 residue is the site phosphorylated by MAPKs in cPLA2 [41]. In this study,
we examined the effects of MAPK inhibitors, U0126
(MEK1/2-ERK1/2 inhibitor), SB202190 (p38 MAPK
inhibitor), and SP600125 (JNK inhibitor) on cPLA2
phosphorylation after stimulation by LPS at 2 h poststimulation and by IFNγ at 8 h post-stimulation in
BV-2 cells. Results demonstrated that among the inhibitors tested, U0126 inhibited Ser505 phosphorylation in a dose-dependent manner whereas SB202190
and SP600125 were not effective (Fig. 3a, c). Similar
results were observed with IFNγ (Fig. 3b, d). These results
are consistent with the notion that phospho-ERK1/2

serves as the primary regulator of cPLA2 phosphorylation
in microglia cells.
LPS- and IFNγ-induced iNOS expression and NO production
are significantly decreased in microglia deficient in cPLA2

In this study, primary microglial cells isolated from
WT and cPLA2−/− homozygous KO mice brains were
used to test for their ability to induce iNOS expression and NO production upon stimulation with LPS
or IFNγ. As expected, cPLA2 expression was blunted
in microglia isolated from the cPLA2 KO brain as
compared to the WT brain (Fig. 4a). Under the same
conditions, LPS-induced iNOS expression and NO
production were significantly decreased in microglia
isolated from the cPLA2 KO brain as compared to
the WT brain (Fig. 4a, b, d). Similarly, IFNγ-induced
iNOS expression and NO production were also significantly decreased in microglial cells from the
cPLA2 KO brains (Fig. 4a, c, d). The concentration of
LPS and IFNγ used in our experiment was shown not
to cause significant cell death at the given time points
(Additional file 1: Figure S1).

Fig. 2 Time course of protein expression in primary microglia and BV-2 cells after LPS/IFNγ stimulation. Primary microglial cells were stimulated
with a 200 ng/mL LPS or b 20 ng/mL IFNγ. Cells were lysed, and proteins were collected and processed at indicated time post-stimulation.
Western blot was performed to determine protein expression. Similarly, the same procedure was performed with BV-2 cells stimulated with
c 200 ng/mL LPS or d 20 ng/mL IFNγ. Results are representative blots of two independent time course experiments for primary microglia and
three experiments for BV-2 cells
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Fig. 3 ERK1/2 contributed to cPLA2 phosphorylation after LPS/IFNγ stimulation. BV-2 cells were starved for 3 h in serum-free DMEM. One hour
prior to stimulation, cells were pretreated with indicated concentrations of MAPK inhibitors: U0126 (U) for ERK1/2 inhibition, SB202190 (SB) for
p38 MAPK inhibition, and SP600125 (SP) for JNK inhibition. Cells were then stimulated with a, c 200 ng/mL LPS or b, d 20 ng/mL IFNγ. Cells were
lysed and proteins were collected and processed 2 h after LPS stimulation or 8 h after IFNγ stimulation for Western blot analyses. a, b Representative
blots. Protein expression was quantified with QuantityOne software for three separate experiments for c LPS-stimulated BV-2 cells and d IFNγ-stimulated
BV-2 cells. Results were expressed as the mean ± SEM (n = 3) and significant difference from the respective group was determined by one-way ANOVA
followed by Dunnett’s post-tests, *P < 0.05; **P < 0.01

LPS- and IFNγ-induced ROS from WT and cPLA2 KO microglia

Our earlier study demonstrated the temporal profile and
mechanism for LPS and IFNγ to induce ROS production
in BV-2 microglial cells [39]. In this study, we attempted
to compare ROS production between primary microglia
isolated from WT and cPLA2 KO brains. In WT primary
microglial cells, ROS production was maximally increased
after stimulation with 200 ng/mL LPS and continued to
increase for 48 h (Fig. 5a). ROS induced by IFNγ was not
significantly increased at 24 h but continued to rise at
48 h (Fig. 5b). Under the same conditions and stimulus
concentrations, neither LPS nor IFNγ managed to cause
significant increase in ROS production in primary microglia isolated from cPLA2 KO brain (Fig. 5c, d).
Pharmacological inhibition and siRNA of cPLA2 result in
suppression of LPS- and IFNγ-induced NO production in
BV-2 cells

Based on the above data suggesting a link between cPLA2
and LPS/IFNγ-induced NO production, we further tested
whether inhibition of cPLA2 by pharmacological inhibitors
and by siRNA knockdown may alter the ability for LPS
and IFNγ to stimulate NO in BV-2 microglial cells. In
this study, two pharmacological inhibitors were used:

AACOCF3, a non-specific PLA2 inhibitor known to suppress activity of both cPLA2 and iPLA2, and pyrrophenone, a specific cPLA2 inhibitor. As shown in Fig. 6a–d,
both inhibitors showed dose-dependent suppression of
NO generation 16 h after LPS and IFNγ stimulation. The
doses of AACOCF3 and pyrrophenone used in this study
were verified to not cause toxicity in the culture system
using the WST-1 assay while aiming for reasonable level
for maximum effect (data not shown).
RNA interference was further employed to ensure the
inhibition observed above was not resulted from nonspecific pharmacological effects. Using the cPLA2 siRNA
(NM_008869, Qiagen) and RNAiMAX transfection reagent, we were able to knockdown cPLA2 by 70–80 %,
based on protein expression by Western blot (Additional
file 2: Figure S2). Under this condition, NO production
was significantly suppressed in knockdown cultures as
compared with control cultures (Fig. 6e, f ).
Pharmacological inhibition and siRNA of cPLA2 result in
significant suppression of LPS- and IFNγ-induced ROS
production in BV-2 cells

Our previous study demonstrated that ROS production
from NADPH oxidase activation plays a major role in
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Fig. 4 iNOS expression and NO production were significantly reduced in cPLA2 KO primary microglia culture compared with WT culture. DIV5–7
primary microglia culture isolated from cPLA2 KO or WT mice were stimulated with 200 ng/mL LPS or 20 ng/mL IFNγ for 24 h. Cells were then
lysed, and proteins were collected/processed. a iNOS/cPLA2/β-actin expressions were demonstrated by Western blot, and b, c iNOS/ β-actin levels
were quantified with the QuantityOne software. Results were expressed as the mean ± SEM (n = 3), and significant difference between the respective paired groups was determined by t test, *P < 0.05; **P < 0.01. d Conditioned mediums from 48 h post-stimulation samples were collected
for determination of nitrite concentration with the Griess protocol. Results were expressed as the mean ± SEM (n = 3) and significant difference
between the respective groups was determined by t test, ***P < 0.001; ^^^P < 0.001

microglia activation and it precedes iNOS induction and
NO production (Chuang et al. 2013). In this study,
cPLA2 inhibitors and siRNA were used to test the link
between cPLA2 and LPS- or IFNγ-induced ROS production in BV-2 cells. As shown in Fig. 7a–d, both

AACOCF3 and pyrrophenone dose-dependently inhibited LPS- or IFNγ-induced ROS production where measured at 12 h post-stimulation. Similarly, siRNA also
significantly diminished ROS induction by the two stimuli (Fig. 7e, f ).
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Fig. 5 Primary microglia from cPLA2 KO mice did not show a significant increase in ROS production by LPS and IFNγ. Different concentrations of
a LPS or b IFNγ, as well as incubation time were used to evaluate the ROS production by primary microglia isolated from wild-type mice. Based
on the results from WT culture, ROS production was evaluated at 48 h post-stimulation with different doses of c LPS or d IFNγ in microglial cells
from cPLA2 KO mice. ROS production was quantified by CM-H2DCFDA fluorescence as described in the text. Results were expressed as the mean ±
SEM (n = 3 WT LPS, n = 8 WT IFNγ, n = 3 KO LPS, n = 3 KO IFNγ), and significant difference between the groups was determined by one-way ANOVA
followed by Dunnett’s post-tests, *P < 0.05; **P < 0.01; ***P < 0.001

cPLA2 inhibition prevents morphological changes
associated with activation in primary microglia

Ca2+-independent PLA2 does not alter LPS- and
IFNγ-induced iNOS/NO/ROS production

In order to visualize the morphological changes of
microglia under activation by LPS or IFNγ, primary
microglia were cultured in coverslips, followed by fixation and immunostaining with Iba-1 (red), marker for
microglial cells and phalloidin (green) for actin filaments. Undisturbed microglia cells were uniform in size
and displayed small round cytoplasm with an offcentered nucleus, resembling the resting ramified
phenotype (Fig. 8a, b). At 24 h after LPS stimulation,
there was obvious expansion of cytoplasmic space with
significant formation of filopodia (Fig. 8c, d). Cells
treated with IFNγ appeared to show higher Iba1 staining
with cytoplasm more spread out like a fried egg. Some
also showed extensive budding around the periphery
(Fig. 8e, f ). There were also increased mitotic events as
evident by cells with di-nuclei in both types of stimulation. Interestingly, microglia pretreated with 5 μM of
AACOCF3 for 1 h prior to LPS or IFNγ stimulation
showed preservation of morphology resembling closely
to unstimulated ramified microglia in the control plates
(Fig. 8g–j).

cPLA2 and iPLA2 are both constitutively expressed
in most cell types, and are both possible contributors to AA production along with its downstream
cascade. While we had established cPLA2 to play
crucial role in microglia activation, it is also important to investigate whether iPLA2 may also play a
role in this process. Using the Miltenyi Biotec
MACS cell separation system, primary microglial
cells were isolated from WT and iPLA2 KO brains.
As shown in Fig. 9a, expression of iPLA2 was not
observed in the iPLA2 KO brains, and stimulation
with LPS did not result in a significant difference in
iNOS expression and NO production between WT
and KO microglia (Fig. 9b, c).
To further verify the results, we also tested
whether selective iPLA2 inhibitor BEL (racemic) may
have an effect on LPS- and IFNγ-induced NO and
ROS production in BV-2 cells. As shown in Fig. 9d–g,
results indicated that BEL did not significantly affect
the amount of NO or ROS produced by either
stimulus.
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Fig. 6 NO production in BV-2 cells after LPS or IFNγ stimulation was inhibited by cPLA2 pharmacological inhibitors or siRNA knockdown. BV-2 cells
were starved for 4 h in serum-free DMEM. One hour prior to stimulation, cells were pretreated with the indicated concentrations of cPLA2 inhibitors:
a, b AACOCF3 or c, d pyrrophenone. Cells were then stimulated with a, c 200 ng/mL LPS or b, d 20 ng/mL IFNγ. Alternatively, BV-2 cells were transfected
with siRNA against cPLA2 for 24 h before being stimulated with e 200 ng/mL LPS or f 20 ng/mL IFNγ. For all experiments, conditioned mediums were
collected 16 h post-stimulation and NO concentrations were measured by Griess protocol as described in the text. Results were expressed as the
mean ± SEM (n = 3) and significant difference between the respective groups was determined by one-way ANOVA followed by Dunnett’s post-tests,
**P < 0.01; ***P < 0.001

cPLA2-dependent induction of NO or ROS in microglia
does not go through COX-1/2

cPLA2 is responsible for AA production and downstream
eicosanoid production. AA can be converted by COX-1/2
into prostaglandin H2 which is further metabolized to
prostaglandins, prostacyclin, and thromboxanes. Alternatively, AA can also go through the lipoxygenase (LOX)
pathway to generate 5/12/15-hydroperoxyeicosatetraenoic
acid (HPETE). COX-1/2 and prostaglandins have always
been implicated in inflammatory processes and COX-1/2
remains a popular target of anti-inflammatory therapy by
non-steroidal anti-inflammatory drugs (NSAIDs). In the
following experiments, we tested the involvement of
COX-1/2 in NO/ROS production in BV-2 cells. Using the
ELISA protocol, we measured the concentration of PGE2

in conditioned medium of BV-2 microglial cell cultures
after stimulation with LPS or IFNγ. We further investigated the effect of ibuprofen, a non-selective reversible
COX-1/2 inhibitor, to inhibit PGE2 production. Results
showed a dose-dependent inhibition of LPS- and IFNγinduced PGE2 by ibuprofen (Fig. 10a, b). We further
tested whether ibuprofen could inhibit LPS- and IFNγinduced NO and ROS in BV-2 cells. Interestingly, ibuprofen did not exert inhibitory effects on either LPS- or
IFNγ-induced NO and ROS production (Fig. 10c–f).
LOX inhibition significantly suppresses cPLA2-dependent
microglial induction of ROS and NO

cPLA2-induced AA release can be metabolized by either
COX or LOX. Since the above results indicated that
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Fig. 7 ROS production in BV-2 cells after LPS or IFNγ stimulation was inhibited by cPLA2 pharmacological inhibitors or siRNA knockdown. BV-2
cells were starved for 4 h in serum-free DMEM. One hour prior to stimulation, cells were pretreated with the indicated concentrations of cPLA2
inhibitors: a, b AACOCF3 or c, d pyrrophenone. Cells were then stimulated with a, c 200 ng/mL LPS or b, d 20 ng/mL IFNγ. Alternatively, BV-2 cells
were transfected with siRNA against cPLA2 24 h before being stimulated with e LPS or f IFNγ. For all experiments, ROS production was measured 12 h
post-stimulation by CM-H2DCFDA fluorescence as described in the text. Results were expressed as the mean ± SEM (n = 3) and significant difference
between the respective groups was determined by one-way ANOVA followed by Dunnett’s post-tests, **P < 0.01, ***P < 0.001

COX played a minimal role in ROS/NO production, experiments were directed to test whether the LOX pathways may mediate LPS- and IFNγ-induced ROS and NO
production. The LOX products have been shown to provide an important role in mediating the downstream inflammatory leukotrienes in neurodegenerative conditions
and infectious processes [42]. When BV-2 cells were pretreated with NDGA, a non-selective LOX inhibitor, NO
and ROS production was significantly suppressed in a
dose-dependent manner (Fig. 11a–d).
Among the lipoxygenases, LOX-5, LOX-12, and
LOX-15 are the most studied and are responsible for
the generation of 5-HPETE, 12-HPETE, and 15HPETE, respectively. To further investigate which
LOX and its subsequent products were responsible for

LPS- or IFNγ-induced ROS and NO production in
microglia, we incorporated the use of zileuton, NCTT956, and PD146176, previously described selective inhibitors for LOX-5, LOX-12, and LOX-15, respectively
[43–45]. While zileuton at varying concentrations did
not seem to affect production of either NO or ROS
production by BV-2 cells after LPS stimulation
(Fig. 12a, b), both NCTT-956 and PD146176 inhibited
ROS/NO production in a concentration-dependent
manner (Fig. 12c–f ). Similar results were seen when
BV-2 cells were stimulated by IFNγ (Additional file 3:
Figure S3A–F). These results thus provided information that LPS- and IFNγ-induced ROS and NO in
microglial cells may be regulated by LOX-12/15 and
not LOX-5.
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stimulation. To ensure that the findings are not a result
of alternative mechanisms from long-term functional
compensation in response to cPLA2 knockout, the same
conclusion was reached using pharmacological inhibition, with AACOCF3 (non-specific) and pyrrophenone
(specific), and RNA interference knockdown in BV-2
cells. Other studies using LPS but not IFNγ as a stimulator support this conclusion in rat primary microglia [30]
and BV-2 cells [48]. On the other hand, while iPLA2 is
also constitutively expressed in microglia and a target of
AACOCF3, results here with iPLA2 KO and pharmacological inhibition with BEL showed that this PLA2 has
little role in mediating ROS and NO production in the
BV-2 microglial cells. This result is in slight contrast to
the prior study by Strokin et al., who suggested that
iPLA2 also contributes to the proinflammatory responses
in LPS-treated astrocytes via Ca2+ signaling [49]. This
difference may well be due to use of different cell type,
i.e., microglia versus astrocytes.
The ERK1/2-cPLA2-ROS-iNOS axis in microglial activation

Fig. 8 cPLA2 inhibition with AACOCF3 prevented morphological
transformation of primary microglia associated with M1 activation.
Immunocytochemical staining for Iba-1 and phalloidin was performed
with DIV5 primary microglia culture with the following treatments for
24 h: a, b control; c, d 200 ng/mL LPS; e, f 20 ng/mL IFNγ; g, h 1 h of
5 μM AACOCF3 pretreatment with 200 ng/mL LPS for 24 h; i, j 1 h of
5 μM AACOCF3 pretreatment with 20 ng/mL IFNγ for 24 h. Iba-1
expression is represented by red fluorescent signal, phalloidin expression
is represented by green fluorescent signal, and nuclear Hoechst staining
is demonstrated in blue

Discussion
cPLA2 plays a significant role in microglial activation

cPLA2 has been shown to play a significant role in mediating oxidative/nitrosative and inflammatory responses
in neurons, astrocytes, and other cells [46, 47], but less
attention has been paid to microglia. The findings of this
study clearly demonstrate the involvement of cPLA2 in
LPS- and IFNγ-induced ROS and NO production in
microglial cultures. To our knowledge, this is the first
study to use primary microglia prepared from cPLA2
and iPLA2 knockout mice to provide new evidence for
the significant role of cPLA2 in microglial activation.
The comparison between cPLA2 knockout and wildtype primary microglia cells showed that cPLA2 not only
plays a crucial role in activating the oxidative/inflammatory pathway, leading to generation and release of ROS/
NO, but also to the overall morphological transformation of microglial cells after endotoxin/cytokine

cPLA2 is known to have multiple active serine residues
susceptible for phosphorylation. Among these serine residues, Ser505 was identified to be phosphorylated by
MAPK and served as an important regulator for cPLA2
activity and subsequent AA release [32, 41]. In the study
by Pavicevic with vascular smooth muscle cells, phosphorylation of Ser515 by CaMKII was shown to precede
Ser505 phosphorylation and phosphorylation of both
Ser515 and 505 sites is required for activation of this enzyme [50]. In primary neurons in culture, stimulation
with ionotropic glutamate receptor agonist such as
NMDA resulted in ROS production through NADPH
oxidase and rapid activation of ERK1/2 and cPLA2 [31].
In this study, we demonstrated that LPS and IFNγ each
mediated a time-dependent increase in phospho-ERK1/2
and cPLA2 in both primary and BV-2 microglial cells. In
both conditions, the time for increase in p-ERK1/2 preceded that for p-cPLA2. The relationship between pERK1/2 and cPLA2 was further confirmed by U0126, the
MEK1/2-ERK1/2 inhibitor, which readily abrogated
phosphorylation of cPLA2.
NADPH oxidase in microglia cells has been shown to
play a significant role in neurodegenerative diseases, such
as alcohol-induced neurodegeneration [51], Alzheimer’s
disease [52], and Parkinson’s disease [53]. Previous study
from our laboratory has demonstrated the production of
ROS from NADPH oxidase to be upstream of NO production in BV-2 microglia cells. Our studies further
demonstrated that in BV-2 microglial cells, LPS and IFNγ
can individually stimulate ROS and iNOS/NO through
phosphorylation of ERK1/2 [39, 40]. Study by Ribeiro et
al. (2013) also demonstrated effects of cannabinoid receptor agonists and antagonists to suppress LPS-induced
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Fig. 9 iPLA2 KO primary microglia culture did not alter LPS-induced NO/ROS production. DIV5–7 primary microglia culture isolated from iPLA2β
KO or WT mice were stimulated with 200 ng/mL LPS for 24 h. Cells were then lysed and proteins were collected/processed. a iNOS/cPLA2/β-actin
expressions were demonstrated by Western blot, and b iNOS/ β-actin levels were quantified with the QuantityOne software. c Conditioned
mediums from 48 h post-stimulated samples were collected for determination of nitrite concentration with the Griess protocol. d–g BV-2 cells
were serum starved for 3 h followed by incubation with indicated concentrations of BEL for 1 h before stimulated with d, f 200 ng/mL LPS or
e, g IFNγ. d, e NO production was measured in conditioned medium 16 h post-stimulation by Griess protocol. f, g ROS production was measured
12 h post-stimulation by CM-H2DCFDA. Results were expressed as the mean ± SEM (n = 3) and significant difference between the groups was
determined by t test (primary microglia) and one-way ANOVA followed by Dunnett’s post-tests (BV-2)

microglia activation via ERK1/2, cPLA2, and NF-κB. These
results as well as ours placed LPS and IFNγ activation of
ERK1/2 and cPLA2 upstream of the NF-κB transcriptional
pathway. In rat microglial cells, Szaingurten-Solodkin observed a link between cPLA2 in NADPH oxidase and
iNOS activated by aggregated Abeta1-42, a toxic peptide
cleaved from the amyloid precursor protein [54]. In their
study, it was proposed that cPLA2 regulated NADPH oxidase activity, which in turn caused upregulation of cPLA2,
COX-1/2, and iNOS through an NF-κB-dependent mechanism. Taken together, our results with cPLA2 inhibitors
as well as siRNA knockdown well demonstrated the role
of cPLA2 in mediating ROS and NO production upon
stimulation by LPS and IFNγ. Our results with primary

microglia isolated from cPLA2 KO brain further validated
the link between cPLA2 on ROS and NO production in
these cells.
Role of arachidonic acid and LOX in microglial activation

Earlier studies had linked cPLA2 or its downstream metabolites (i.e., AA or lysophospholipids) with ROS production from NADPH oxidase, although the exact
mechanism remains to be investigated [55, 56]. In macrophages, there is evidence that cPLA2 can interact directly with NADPH oxidase subunits, namely p47phox
and p67phox, which facilitate translocation of these subunits to membranes to form the active NADPH oxidase
complex [55, 57]. Alternatively, downstream products of
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Fig. 10 Ibuprofen dose-dependently inhibited the PGE2 production after LPS/IFNγ stimulation but did not affect the NO/ROS production in BV-2
cells. BV-2 cells were serum starved for 3 h followed by incubation with indicated concentrations of ibuprofen for 1 h before stimulated with a, c,
e 200 ng/mL of LPS or b, d, f 20 ng/mL of IFNγ. a, b PGE2 production was measured in conditioned medium 16 h post-stimulation by the PGE2
ELISA assay as described in the text. c, d NO production was measured in conditioned medium 16 h post-stimulation by Griess protocol. e, f ROS
production was measured 12 h post-stimulation by CM-H2DCFDA. Results were expressed as the mean ± SEM (n = 3) and significant difference
between the respective groups was determined by one-way ANOVA followed by Dunnett’s post-tests, ***P < 0.001

AA were proposed to be involved in ROS production
from NADPH oxidase [58]. Activation of cPLA2 and
subsequent release of AA has been shown in the production of an array of eicosanoids, including the production
of prostaglandins and leukotrienes through activation of
COX and LOX. However, the extent for this action is
cell dependent [42]. A number of studies, including
those from our own, have demonstrated the increase in
PGE2 production upon stimulation with LPS and IFNγ
in astroglial cells [59, 60]. In the present study with
microglial cells, we showed that while the COX-1/2 inhibitor effectively inhibited LPS- and IFNγ-induced
PGE2 production, this condition was not linked to the
suppression of ROS and NO production by LPS and
IFNγ.

While the action of COX-1/2 is well established in
peripheral inflammation and a popular target for nonsteroidal anti-inflammatory drugs (NSAIDs), its role in
neuroinflammation is not well understood. Aspirin is
used after acute stroke not for anti-inflammatory effect
but rather for secondary prevention of atherosclerosis
due to its antiplatelet properties through inhibition of
prostaglandin and subsequent thromboxane A2 [61, 62].
Similarly, numerous recent large-scale double-blind
placebo-controlled clinical trials have not found a beneficial effect of COX-1/2 inhibition in the treatment of
neurological diseases where neuroinflammation is proposed to be involved, such as Alzheimer’s disease or depression [63, 64]. In agreement with our study, Minghetti
and colleagues have also reported that microglial cell

Chuang et al. Journal of Neuroinflammation (2015) 12:199

Page 16 of 20

Fig. 11 LOX inhibition mitigated NO or ROS production in BV-2 cells after LPS or IFNγ stimulation. BV-2 cells were serum starved for 3 h followed
by incubation with indicated concentrations of NDGA for 1 h before stimulated with a, c 200 ng/mL LPS or b, d 20 ng/mL IFNγ. a, b NO production
was measured in conditioned medium 16 h post-stimulation by Griess protocol. c, d ROS production was measured 12 h post-stimulation by
CM-H2DCFDA. Results were expressed as the mean ± SEM (n = 3) and significant difference between the respective groups was determined by
one-way ANOVA followed by Dunnett’s post-tests, *P < 0.05; **P < 0.01; ***P < 0.001

activation increased TNFα and COX-1/2, but this condition did not contribute to ROS/NO production [65, 66].
On the other hand, recent studies have generating
growing recognition of LOX in mediating inflammation,
and some have implicated its role in neuroinflammation.
Lipoxygenases are known to mediate the pathophysiology of numerous inflammatory diseases, including
asthma, immune disorders, and cancer. Parallel to the
action of COX-1/2 for the biosynthesis of prostaglandins
from AA, lipoxygenases mediate the biosynthesis of leukotrienes and eoxins from AA, all of which are eicosanoids that play a significant role in inflammation and
immune function [42]. Of note, the ability for LOX-15
to generate eoxin has been identified as a novel pathway
of inflammatory responses in mast cells and eosinophils
[67] and as a promising novel target against asthma [68].
Genetic ablation of LOX-12/15, but not LOX-5, was
shown to protect against denervation-induced muscle atrophy [69]. In the central nervous system, LOX-12/15
was shown to have increased expression in oligodendrocytes and microglia of periventricular leukomalacia [70],
and disease phenotype was ameliorated by absence of
LOX-12/15 in animal models of Alzheimer’s disease
[71]. The LOX-5 pathway has also been associated with
Alzheimer’s disease and other neurodegenerative conditions [72]. Although the mechanism of how LOX causes

microglial activation and neuroinflammation remains to
be elucidated, our results provided evidence suggesting
that LOX activation in microglial cells plays a crucial
role leading to induction of ROS and NO. To our knowledge, this is the first finding to biochemically connect
cPLA2 pathway to oxidation and inflammatory responses
in microglial cells through LOX. Future studies should
further examine the specific involvement of LOX isoforms in proinflammatory gene expression and regulation of ROS production in microglial cells.
cPLA2 as a therapeutic target against neurological
diseases

Since the 1990s, cPLA2 has been demonstrated to be a favorable target for intervention against a wide range of
neurological diseases. Using an experimental stroke
model, Bonventre et al. was the first to show that cPLA2
knockout mice suffered less ischemic damage and had
smaller infarct volume after transient middle cerebral artery occlusion [21]. Sanchez-Mejia et al. also demonstrated transgenic hAPP mice with cPLA2 knockout to
exhibit significantly less cognitive deficit compared with
cPLA2 intact transgenic hAPP mice, indicating a potential
role of cPLA2 in the pathogenesis of Alzheimer’s disease
[73]. AACOCF3, a non-selective cPLA2 and iPLA2 inhibitor, was discovered to be an effective pharmacological
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Fig. 12 NO/ROS production by BV-2 cells after LPS stimulation was mitigated by LOX-12/15 inhibition, but not by LOX-5 inhibition. BV-2 cells
were serum starved for 3 h followed by 1-h incubation with indicated concentrations of LOX inhibitors: a, b zileuton for LOX-5 inhibition; c, d
NCTT-956 for LOX-12 inhibition; and e, f PD146176 for LOX-15 inhibition. The cells were then stimulated with 200 ng/mL LPS. a, c, e NO production
was measured in conditioned medium 16 h post-stimulation by Griess protocol. b, d, f ROS production was measured 12 h post-stimulation with
CM-H2DCFDA fluorescence. Results were expressed as the mean ± SEM (n = 3), and the significant difference between the respective groups was
determined by one-way ANOVA followed by Dunnett’s post-tests, *P < 0.05; **P < 0.01; ***P < 0.001

inhibitor of PLA2. Due to its physicochemical properties,
it can readily penetrate into cell membranes. In thrombinstimulated platelets, in Ca2+ ionophore-stimulated human
monocytic cells, and in interleukin 1-stimulated mesangial

cells, all liberation of AA is essentially blocked at a concentration of 5 to 20 μM [74, 75]. Since the discovery and
popularization of AACOCF3, more recent studies further
demonstrated the administration of cPLA2 pharmacologic
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inhibitor to offer protective effect against multiple neurological diseases. This includes the amelioration of focal ischemic damage in experimental stroke [28], prevention of
secondary tissue damage in experimental autoimmune
encephalitis, an in vivo model for multiple sclerosis
[30], as well as preservation of neuronal survival and
retention of motor function in a mouse model of spinal
cord injury [29, 76].
While most of the studies suggested and focused on
the action of cPLA2 in the neurons in the event of neurodegeneration and neuronal apoptosis, less attention
was given to the potential role of cPLA2 in the microglia
cells. While microglia activation plays an important role
to limit neuronal damage and phagocytose cellular debris and foreign pathogens, M1 activation of microglia
cells can also promote microglia-induced neuronal damage and further propagate ongoing neuroinflammation.
The results of this study had shed light on one potential
mechanism of M1 microglia activation, which can potentially be targeted and controlled. Interestingly, inhibition of cPLA2 by AACOCF3 was able to abrogate the
morphological changes elicited by LPS and IFNγ in WT
primary microglial cells. We believe that cPLA2 inhibition not only prevents microglia activation but more
importantly becomes a viable therapeutic strategy to impede neuronal cell death by limiting secondary neuronal
damage. In this regard, inhibiting PLA2 cascade has been
considered an essential strategy for opposing microglia activation [77] and discovering new and synthetic inhibitors
for PLA2 will be an important future endeavor for understanding and treatment of neurological disorders [78].

Conclusions
This study demonstrated a crucial role of cPLA2 in the activation of microglial cells, specifically in LPS- and IFNγstimulated ROS and iNOS/NO production. In addition,
cPLA2 also controls the morphological transformations associated with microglial activation. Upon looking at the
downstream pathways, results show that LPS- and IFNγinduced activation of ROS/NO is dependent on LOX-12/15
and not COX-1/2, thus offering new insights into the signaling pathway during microglia activation. Further studies
are needed to better understand the molecular mechanisms
underlying cPLA2 in microglial activation and how this
may offer novel therapeutic options for the prevention
and/or treatment of neuroinflammatory/neurodegenerative
diseases.

Page 18 of 20

protocol as described in the text. Results were expressed as the mean ±
SEM (n = 3) and significant difference compared with the control group
was determined by one-way ANOVA followed by Dunnett’s post-tests,
**P < 0.01, ***P < 0.001.
Additional file 2: Figure S2. cPLA2 protein expression level decreased
significantly after siRNA knockdown. Representative blot demonstrating
protein levels of cPLA2 and β-actin in BV-2 cells between groups: (1) control,
(2) BV-2 cells were transfected with negative control siRNA for 24 h, and (3)
BV-2 cells were transfected with siRNA against cPLA2 for 24 h.
Additional file 3: Figure S3. NO/ROS production by BV-2 cells after IFNγ
stimulation was mitigated by LOX-12/15 inhibition, but not by LOX-5
inhibition. BV-2 cells were serum starved for 3 h followed by 1-h incubation
with indicated concentrations of LOX inhibitors: (A–B) zileuton for LOX-5
inhibition, (C–D) NCTT-956 for LOX-12 inhibition, and (E–F) PD146176 for
LOX-15 inhibition. The cells were then stimulated with 20 ng/mL IFNγ.
(A, C, E) NO production was measured in conditioned medium 16 h poststimulation by Griess protocol. (B, D, F) ROS production was measured 12 h
post-stimulation with CM-H2DCFDA fluorescence. Results were expressed as
the mean ± SEM (n = 3) and significant difference between the respective
groups was determined by one-way ANOVA followed by Dunnett’s posttests, *P < 0.05; ***P < 0.001.
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